Professional Marketing briefs
Valeant Pharmaceuticals entered into an agreement with Spear Pharmaceuticals for rights to commercialize Refissa, a prescription wrinkle and sun damage cream. Valeant will pay $12 million and the companies will share netprofit.
Arena Pharmaceuticals is looking for a commercial partner for its weight loss drug lorcaserin, pending approval, but will launch without if need be, the company told Reuters. The company is competing with Vivus Inc and Orexigen Therapeutics for first-to-market status.